Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis

Alcoholic Liver Cirrhosis Clinical Trial

Official title:
A Parallel Group Randomized Open Blinded End Point Evaluation, Multicentric, Dose Escalation, Phase -II Study Assessing the Safety and Efficacy of Intraarterial (Hepatic) Ex-vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Alcoholic Liver Cirrhosis

Status Completed

Clinical Trial Summary

This study will evaluate the safety and efficacy of mesenchymal stem cells in patients with cirrhosis of liver. Stem cells will be injected into the hepatic artery. Improvement in various parameters will be observed over 2 years.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01591200
Study type	Interventional
Source	Stempeutics Research Pvt Ltd
Contact
Status	Completed
Phase	Phase 2
Start date	June 2012
Completion date	April 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01741090` - The Effectiveness and Safety for Mesenchymal Stem Cell for Alcoholic Liver Cirrhosis	Phase 2
Recruiting	`NCT00239096` - Prevention of Decompensation in Liver Cirrhosis	Phase 4
Completed	`NCT01875081` - REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)	Phase 2
Completed	`NCT02806011` - Long-term Follow-up Study of Livercellgram in Alcoholic LC Patients Who Completed Livercellgram Phase 2 Study
Recruiting	`NCT03838250` - Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC	Phase 1